At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 341 enrolled
Drug / intervention
SEP-225289 +2 moredrug
Likely dose
SEP-225289 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Parallel Group, Multicenter Efficacy and Safety Study of SEP-225289 Versus Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
In Brief
A Phase 2 clinical trial evaluating SEP-225289 and Placebo for Adult Attention Deficit Hyperactivity Disorder. Completed, enrolled 341 participants across 31 sites.
Detailed Summary
A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartDec 2012
Primary CompletionNov 2013
Study CompletionDec 2013
TodayJul 2026
First PostedSep 25, 2012
Enrollment StartDec 1, 2012
Primary CompletionNov 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 13.8 years ago
Interventions
SEP-225289drug
SEP-225289 4mg once daily
SEP-225289drug
SEP-225289 8mg once daily
Placebodrug
Placebo once daily